Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 6:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 455 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Solution Vehicle Clear all
Active, not recruiting Phase 3 Interventional

Iltamiocel Compared to Placebo for Chronic Fecal Incontinence in Females With Obstetric Injury

NCT05776277
View directory record Official record
Conditions
Fecal Incontinence
Interventions
Iltamiocel, Placebo
Biological · Other
Lead sponsor
Cook MyoSite
Industry
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
25
States / cities
La Jolla, California • Orange, California • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 24, 2026, 6:14 AM EDT
Completed Phase 1 Interventional Results available

Phase I Photodynamic Therapy (PDT) for Benign Dermal Neurofibromas (NF1)

NCT01682811
View directory record Official record
Conditions
Neurofibromatoses
Interventions
Part 1 Levulan injection, Part 1 Levulan surface application, Part 1 Levulan surface application twice, Part 1 Levulan surface application twice with microneedling, Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 1, Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 2, Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 3
Drug
Lead sponsor
Harry T Whelan, MD
Other
Eligibility
18 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 18, 2021 · Synced Oct 24, 2026, 6:14 AM EDT
Completed Phase 2 Interventional Results available

A Phase2 of A-101 Topical Solution in Subjects With Common Warts

NCT03210337
View directory record Official record
Conditions
Common Wart
Interventions
A-101 Topical Solution, A-101 Vehicle Solution
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
8 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
17
States / cities
Scottsdale, Arizona • Rogers, Arkansas • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated May 1, 2019 · Synced Oct 24, 2026, 6:14 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Clinical Effect, Pharmacokinetics , Safety, and Tolerability of Umeclidinium in Palmar Hyperhidrosis Subjects

NCT02673619
View directory record Official record
Conditions
Hyperhidrosis
Interventions
Umeclidinium, Vehicle
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
5
States / cities
Omaha, Nebraska • Raleigh, North Carolina • Austin, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2018 · Synced Oct 24, 2026, 6:14 AM EDT
Completed Phase 2 Interventional Results available

A Study of Safety and Efficacy of UNR844 Chloride (UNR844-Cl) Eye Drops in Subjects With Presbyopia.

NCT03809611
View directory record Official record
Conditions
Presbyopia
Interventions
UNR844-Cl, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
45 Years to 65 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
14
States / cities
Mission Hills, California • Newport Beach, California • Largo, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated May 11, 2022 · Synced Oct 24, 2026, 6:14 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Nyxol Eye Drops as a Single Agent and With Adjunctive Low-Dose Pilocarpine Eye Drops in Subjects With Presbyopia

NCT05646719
View directory record Official record
Conditions
Presbyopia
Interventions
Phentolamine Opthalmic Solution 0.75%, Placebo, Low dose pilocarpine, Low dose pilocarpine vehicle
Drug · Other
Lead sponsor
Opus Genetics, Inc
Industry
Eligibility
40 Years to 64 Years
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
26
States / cities
Phoenix, Arizona • Azusa, California • Newport Beach, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 24, 2026, 6:14 AM EDT
Completed Phase 4 Interventional

Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3

NCT04649229
View directory record Official record
Conditions
Heart Failure
Interventions
LCZ 696, Placebo, Para-aminohippurate, Iohexol, Aprepitant
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 24, 2026, 6:14 AM EDT
Terminated Phase 2 Interventional Results available

Relieving Acute Pain (RAP) Study: A Pilot Study

NCT03426137
View directory record Official record
Conditions
Trauma, Opioid Use, Spine Fusion
Interventions
Oxycodone, Ketorolac, Placebo
Drug · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Oct 24, 2026, 6:14 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

A 21-Day Topical Safety Study of Diltiazem Hydrochloride Using a Cumulative Irritant Patch Test Design

NCT01821274
View directory record Official record
Conditions
Skin Irritation
Interventions
Diltiazem Hydrochloride 2% Cream, Vehicle Cream, 0.1% solution o sodium lauryl sulfate (SLS), Saline 0.9%
Drug
Lead sponsor
Ventrus Biosciences, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Paramus, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 21, 2013 · Synced Oct 24, 2026, 6:14 AM EDT
Completed Phase 3 Interventional Results available

A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle

NCT01881113
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
AC-170 0.24%, AC-170 0%
Drug
Lead sponsor
Aciex Therapeutics, Inc.
Industry
Eligibility
10 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 9, 2017 · Synced Oct 24, 2026, 6:14 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of the Safety and Anesthetic Effect of AG-920 Topical Ophthalmic Solution

NCT04513652
View directory record Official record
Conditions
Anesthesia, Local
Interventions
AG-920, Placebo
Drug
Lead sponsor
American Genomics, LLC
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 24, 2026, 6:14 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Preliminary Efficacy of Lipoxin Analog BLXA4-ME Oral Rinse for the Treatment of Gingivitis

NCT02342691
View directory record Official record
Conditions
Gingival Inflammation
Interventions
BLXA4, Placebo oral rinse
Drug
Lead sponsor
The Forsyth Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Oct 24, 2026, 6:14 AM EDT
Completed Phase 4 Interventional

Impact of XDEMVY® on Demodex Blepharitis in Soft Contact Lens Wearers

NCT06182358
View directory record Official record
Conditions
Demodex Blepharitis
Interventions
Lotilaner ophthalmic solution, 0.25%, Vehicle control
Drug
Lead sponsor
Tarsus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
14
States / cities
Cave Creek, Arizona • Long Beach, California • Colorado Springs, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Oct 24, 2026, 6:14 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Ophthalmic Phentolamine Mesylate to Reverse Pharmacologically Induced Mydriasis

NCT04024891
View directory record Official record
Conditions
Mydriasis, Dilation
Interventions
Phentolamine Mesylate Ophthalmic Solution 1%, Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)
Drug · Other
Lead sponsor
Opus Genetics, Inc
Industry
Eligibility
18 Years to 45 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
4
States / cities
Pittsburg, Kansas • Lexington, Kentucky • Athens, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced Oct 24, 2026, 6:14 AM EDT
Completed Phase 2 Interventional Results available

Light Dose Ranging Study of Photodynamic Therapy (PDT) With Levulan + Blue Light Versus Vehicle + Blue Light in Severe Facial Acne

NCT00706433
View directory record Official record
Conditions
Acne Vulgaris
Interventions
aminolevulinic acid HCL (ALA), Vehicle (VEH)
Drug · Other
Lead sponsor
DUSA Pharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
14
States / cities
Hot Springs, Arkansas • San Diego, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2011 · Synced Oct 24, 2026, 6:14 AM EDT
Completed Phase 4 Interventional Results available

Study Assessing Patient Satisfaction With LATISSE® for Increasing Eyelash Prominence

NCT01448525
View directory record Official record
Conditions
Hypotrichosis
Interventions
bimatoprost ophthalmic solution 0.03%, bimatoprost vehicle solution
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated May 22, 2013 · Synced Oct 24, 2026, 6:14 AM EDT
Active, not recruiting Phase 2 Interventional

Stromal Vascular Fraction Cell Therapy to Improve the Repair of Rotator Cuff Tears

NCT03332238
View directory record Official record
Conditions
Rotator Cuff Tear, Muscle Atrophy, Tendon Tear
Interventions
Autologous Stomal Vascular Fraction Material, Ringer's solution
Device
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
45 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 24, 2026, 6:14 AM EDT
Completed Phase 2 Interventional Results available

REC 0/0559 Eye Drops for Treatment of Moderate and Severe Neurotrophic Keratitis in Adult Patients

NCT04276558
View directory record Official record
Conditions
Neurotrophic Keratitis
Interventions
Udonitrectag, Vehicle
Drug · Other
Lead sponsor
RECORDATI GROUP
Industry
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
9
States / cities
Crystal River, Florida • Gainesville, Florida • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 24, 2026, 6:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic Study of GSK2881078 and Study to Evaluate the Effect of CYP3A4 Inhibition on PK of GSK2881078

NCT02567773
View directory record Official record
Conditions
Cachexia
Interventions
GSK2881078, Placebo, Itraconazole
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Oct 24, 2026, 6:14 AM EDT
Recruiting Early Phase 1 Interventional

A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0111 in Patients With Solid Tumors

NCT06700070
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Soft Tissue Sarcoma Adult, Triple Negative Breast Cancer
Interventions
PBA-0111
Drug
Lead sponsor
Pure Biologics S.A.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Oct 24, 2026, 6:14 AM EDT
Completed Phase 2 Interventional Results available

Systemic Bioavailability Study Of Col-118 Administered Topically as a 0.18 % Facial Gel And Brimonidine Ophthalmic Solution 0.2%

NCT00697541
View directory record Official record
Conditions
Erythematous Rosacea
Interventions
0.18% COL-118 facial gel (1.8 mg brimonidine), 0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop), Advanced Eye Relief, COL-118 facial gel vehicle
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Broomall, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 24, 2026, 6:14 AM EDT
Completed Phase 3 Interventional Results available

Tavilermide Ophthalmic Solution for the Treatment of Dry Eye

NCT03925727
View directory record Official record
Conditions
Keratoconjunctivitis Sicca, Dry Eye
Interventions
Tavilermide ophthalmic solution, Placebo
Drug · Other
Lead sponsor
Mimetogen Pharmaceuticals USA, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
623 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
22
States / cities
Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2023 · Synced Oct 24, 2026, 6:14 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis (MIRA-3)

NCT05134974
View directory record Official record
Conditions
Mydriasis, Dilation
Interventions
Phentolamine Ophthalmic Solution 0.75%, Phentolamine Ophthalmic Solution Vehicle
Drug
Lead sponsor
Opus Genetics, Inc
Industry
Eligibility
12 Years and older
Enrollment
368 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
15
States / cities
Newport Beach, California • Westminster, California • Delray Beach, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced Oct 24, 2026, 6:14 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Photodynamic Therapy With Levulan Kerastick + Blue Light for Actinic Keratoses on the Upper Extremities

NCT02137785
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Aminolevulinic Acid (ALA), Topical Solution Vehicle, Blue Light Photodynamic Therapy Illuminator (BLU-U)
Drug · Device
Lead sponsor
DUSA Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
13
States / cities
Fremont, California • San Diego, California • Aventura, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2015 · Synced Oct 24, 2026, 6:14 AM EDT